Interleukin-4 Inhibits Platelet Glycoprotein VI to Reduce Thrombosis in Mice

The Clinical Intersection of Inflammation and Thrombosis

The intricate relationship between systemic inflammation and pathological coagulation is a defining feature of diverse clinical states, from acute sepsis to chronic cardiovascular disease [1, 2]. Clinical data have long established that elevated C-reactive protein, a hepatic acute-phase reactant, serves as a significant predictor for vascular events. Specifically, patients in the highest quartile of C-reactive protein levels face a threefold increased risk of myocardial infarction (relative risk 2.9, p<0.001) and a twofold increased risk of ischemic stroke (relative risk 1.9, p=0.02) [3, 4]. While the role of pro-inflammatory drivers in promoting a prothrombotic state is well-recognized, the mechanisms by which anti-inflammatory cytokines might actively suppress platelet function have remained less characterized [5]. Existing therapies for thromboinflammatory conditions, such as recombinant human activated protein C, which reduces 28-day mortality in severe sepsis from 30.8% to 24.7% (p=0.005), underscore the therapeutic potential of targeting this crosstalk [6]. A recent study now clarifies a key aspect of this molecular dialogue, demonstrating that interleukin-4 directly binds to the platelet receptor glycoprotein VI to suppress collagen-induced platelet aggregation and thrombus formation [7], offering a precise molecular target within this complex interplay.

Molecular Mechanisms of IL-4 Mediated Platelet Inhibition

Interleukin-4 exerts a broad inhibitory effect on the signaling cascade required for platelet activation and recruitment. The study demonstrated that interleukin-4 inhibited collagen-induced intracellular calcium mobilization, a critical secondary messenger flux that triggers downstream effector functions. By dampening this calcium response, the cytokine also inhibited the release of adenosine triphosphate (ATP) from platelet dense granules. For the clinician, suppressing ATP release is particularly relevant because extracellular ATP acts as a potent signaling molecule that recruits additional circulating platelets to the site of vascular injury, thereby amplifying the growth of a developing thrombus. Beyond these internal signals, interleukin-4 significantly altered the expression of surface markers essential for clot integrity. The findings showed that interleukin-4 inhibited the expression of P-selectin, a key adhesion molecule that facilitates the interaction between platelets, leukocytes, and the vascular endothelium. Crucially, the researchers also found that interleukin-4 inhibited the activation of integrin alpha-IIb-beta-3, the receptor that serves as the final common pathway for platelet aggregation by binding fibrinogen to cross-link adjacent platelets. The cumulative biochemical impact of these actions resulted in distinct changes to the physical behavior of platelets, as interleukin-4 inhibited platelet spreading, a morphological transition where platelets flatten to increase their surface area contact with the subendothelial matrix. This impairment of functional architecture, combined with the suppression of activation markers, provides a molecular explanation for how anti-inflammatory states may naturally mitigate thrombotic risk.

Direct Binding to the Glycoprotein VI Collagen Domain

The study identified a direct physical interaction as the basis for interleukin-4's antithrombotic activity. Molecular mapping revealed that interleukin-4 binds to residues 38-46 within the extracellular collagen-binding domain of glycoprotein VI (GPVI). This specific binding is critical because GPVI is the major platelet receptor responsible for initial adhesion to exposed subendothelial collagen at sites of vascular injury. By occupying this site, interleukin-4 physically obstructs the receptor's ability to engage its ligand, thereby preventing the initiation of the pro-thrombotic cascade. This physical blockade translates into a significant reduction in intracellular signaling, as the study found that interleukin-4 suppresses downstream signaling by inhibiting phosphorylation of both phospholipase Cγ2 (PLCγ2) and protein kinase C (PKC). For the clinician, this dual inhibition is profound, as these two enzymes are central mediators that trigger the release of internal calcium stores and the secretion of platelet granules, respectively. To confirm the specificity of this interaction, the researchers designed a GPVI-derived interfering peptide, named RR9, which binds directly to interleukin-4. This peptide acts as a molecular decoy, sequestering the cytokine. The experiments demonstrated that RR9 disrupted the interleukin-4-GPVI complex and reversed the inhibitory effects of interleukin-4 on platelets, restoring their normal reactive capacity and confirming that this specific molecular interaction is the primary mechanism of inhibition.

In Vivo Evidence of Antithrombotic Activity

To determine if these cellular-level effects translate to systemic physiological changes, the researchers transitioned to in vivo animal models. The study demonstrated that interleukin-4 overexpression or intravenous administration inhibited platelet intracellular calcium mobilization and subsequent ATP release within the circulation, confirming that the cytokine's inhibitory profile is maintained in a complex biological environment. These biochemical changes produced measurable functional outcomes. The researchers observed that interleukin-4 administration prolonged bleeding time, a standard clinical measure of primary hemostasis. Most importantly, this shift in the hemostatic balance provided significant protection against pathological vessel occlusion. The findings showed that interleukin-4 attenuated both arterial and venous thrombosis, suggesting its regulatory mechanism is relevant across the different hemodynamic conditions that characterize these distinct vascular beds. For the practicing physician, these results provide a direct mechanistic link between an anti-inflammatory state driven by interleukin-4 and a reduced risk of thrombotic events, identifying this cytokine as a potent endogenous modulator of the GPVI pathway.

Consequences of IL-4 Deficiency and Receptor Blockade

To complete the investigation, the researchers performed a series of loss-of-function experiments to examine the consequences of the cytokine's absence. In models of genetic deficiency, interleukin-4 knockout enhanced platelet reactivity and promoted hemostasis, effectively lowering the threshold for clot initiation. This hyper-responsive state had direct pathological consequences, as interleukin-4 knockout aggravated thrombosis, leading to more severe vessel occlusion compared to controls. This suggests that endogenous interleukin-4 serves as a constitutive brake on the coagulation system. The researchers then replicated these effects using pharmacological and molecular blockade. Both anti-interleukin-4 antibody treatment and administration of the interfering peptide RR9 enhanced platelet reactivity, promoted hemostasis, and aggravated thrombosis, mirroring the results from the knockout models. By demonstrating that three distinct methods of disrupting the IL-4 pathway yield the same pro-thrombotic phenotype, the findings strongly support the conclusion that this cytokine is a critical negative regulator of hemostasis. For clinicians, these data indicate that modulating interleukin-4 levels or its specific interaction with glycoprotein VI represents a potential therapeutic axis for managing thrombotic disorders.

References

1. Dellinger RP, Levy MM, Carlet J, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine. 2007. doi:10.1007/s00134-007-0934-2

2. Angus DC, Poll TVD. Severe Sepsis and Septic Shock. New England Journal of Medicine. 2013. doi:10.1056/nejmra1208623

3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. New England Journal of Medicine. 1997. doi:10.1056/nejm199704033361401

4. Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Research Reviews. 2016. doi:10.1016/j.arr.2016.08.006

5. Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy. 2021. doi:10.1038/s41392-021-00658-5

6. Bernard GR, Vincent J, Laterre P, et al. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New England Journal of Medicine. 2001. doi:10.1056/nejm200103083441001

7. Lin S, Yin Y, Wang S, et al. Inhibiting thromboinflammation via interleukin-4 binding to platelet glycoprotein VI and suppression of thrombosis.. Blood. 2026. doi:10.1182/blood.2025031889